Stephen Mahoney

Insider Reports History

Entity
Individual
Location
C/O Kiniksa Pharmaceuticals, Ltd., Clarendon House, 2 Church Street, Hamilton, Bermuda
Signature
/s/Stephen Mahoney
All insider transactions
Transactions in reports broken out by “transaction date” reported in original SEC filing, see here for transactions aggregated across transaction date

Holdings reported by Stephen Mahoney:

Stock Role Class Num Shares Value Price $ Report Date Ownership
Viridian Therapeutics, Inc.\DE President and CEO, Director Common Stock 21.4K $499K $23.33 Sep 27, 2024 Direct
Magenta Therapeutics, Inc. Title: Chief Financial and Operating Officer Common Stock 17.3K $207K $12.00 Nov 30, 2022 Direct
Viridian Therapeutics, Inc.\DE President and CEO, Director Stock Option (Right to Buy) 1.26M Oct 30, 2023 Direct
Magenta Therapeutics, Inc. Title: Chief Financial and Operating Officer Stock Option (Right to Buy) 130K Aug 1, 2022 Direct

Insider Reports Filed by Stephen Mahoney

Symbol Company Period Transactions Value $ Form Type Date Filed Role
VRDN Viridian Therapeutics, Inc.\DE Sep 27, 2024 1 $499K 4 Sep 30, 2024 President and CEO, Director
VRDN Viridian Therapeutics, Inc.\DE Oct 30, 2023 1 $0 4 Nov 1, 2023 President and CEO, Director
VRDN Viridian Therapeutics, Inc.\DE Oct 30, 2023 0 $0 3 Nov 1, 2023 President and CEO, Director
DNTH Magenta Therapeutics, Inc. Nov 30, 2022 1 $2.82K 4 Dec 2, 2022 Title: Chief Financial and Operating Officer
DNTH Magenta Therapeutics, Inc. Aug 1, 2022 1 $0 4 Aug 1, 2022 Title: Chief Financial and Operating Officer Exhibit 24.1: Power of Attorney
DNTH Magenta Therapeutics, Inc. May 17, 2022 1 $0 4 May 19, 2022 Title: Chief Financial and Operating Officer
DNTH Magenta Therapeutics, Inc. Feb 15, 2022 1 $0 4 Feb 17, 2022 Title: Chief Financial and Operating Officer
DNTH Magenta Therapeutics, Inc. Sep 16, 2021 1 -$38.6K 4 Sep 20, 2021 Chief Financial and Operating Officer
DNTH Magenta Therapeutics, Inc. Sep 14, 2021 1 $0 4 Sep 16, 2021 Chief Financial and Operating Officer